Application of SELDI-TOF-MS Coupled With an Artificial Neural Network Model to the Diagnosis of Pancreatic Cancer

被引:6
作者
Hu, Qiong-ying [1 ]
Wang, Kai-zheng [1 ]
Ding, Yin-huan [1 ]
Zheng, Lv-fang [1 ]
Liang, Shuang-hua [1 ]
Lei, Zheng-ming [2 ]
Fu, Wen-guang [2 ]
Yan, Li [3 ]
机构
[1] Luzhou Med Coll, Affiliated Hosp, Dept Lab Med, Luzhou, Peoples R China
[2] Luzhou Med Coll, Affiliated Hosp, Dept Hepatobiliary Surg, Luzhou, Peoples R China
[3] Beijing Scilight Biotechnol Ltd Co, Beijing, Peoples R China
来源
LABMEDICINE | 2010年 / 41卷 / 11期
关键词
SELDI-TOF-MS; pancreatic cancer; artificial neural network; calibration; reproducibility; sensitivity; specificity; TRANSITIONAL-CELL CARCINOMA; ENHANCED LASER-DESORPTION; FLIGHT MASS-SPECTROMETRY; PROSTATE-CANCER; OVARIAN-CANCER; PROTEOMIC PATTERNS; SERUM; IDENTIFICATION; SURFACE; EXPRESSION;
D O I
10.1309/LMH6TU0MQKX6V2DN
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: There are no satisfactory biomarkers for screening pancreatic cancer. The surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technique has been used to identify biomarkers for different types of cancers. A new and reliable SELDI proteomic method for diagnosing pancreatic cancer is needed. Methods: Four hundred and fifty-five serum samples were tested by SELDI-TOF-MS matching on a gold chip. Samples were assigned to 1 of 2 subsets according to collection order, viz., a training set, and a testing set. The training set was used to identify statistically significant peaks and to develop the artificial neural network (ANN) model for diagnosing pancreatic cancer. The testing set was used in a blind test to validate the diagnostic efficiency of the ANN model. Results: A total of 62 proteins that differed between patients and controls were identified (P<0.05). Nine of these proteins (P<0.01; m/z at 4218 Da, 4238 Da, 4264 Da, 4480 Da, 5805 Da, 5928 Da, 9033 Da, 9258 Da, and 9299 Da) were chosen to develop the ANN. The model was subjected to a blind test using the testing set for diagnosis of pancreatic cancer. Sensitivity and specificity were 66.67% and 95.98%, respectively, and the accuracy was 93.47%. Conclusion: These preliminary results suggest that patients with pancreatic cancer may have serum proteins that differ from healthy controls. The ANN is a new method for diagnosing and identifying pancreatic cancer.
引用
收藏
页码:676 / 681
页数:6
相关论文
共 23 条
[1]  
Adam BL, 2002, CANCER RES, V62, P3609
[2]   Preanalytical influences in clinical proteomic studies: Raising awareness of fundamental issues in sample banking [J].
Banks, Rosamonde E. .
CLINICAL CHEMISTRY, 2008, 54 (01) :6-7
[3]  
Britten RA, 2005, ONCOL REP, V14, P1323
[4]  
Cazares LH, 2002, CLIN CANCER RES, V8, P2541
[5]   Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry [J].
Engwegen, Judith Y. M. N. ;
Helgason, Helgi H. ;
Cats, Annemieke ;
Harris, Nathan ;
Bonfrer, Johannes M. G. ;
Schellens, Jan H. M. ;
Beijnen, Jos H. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (10) :1536-1544
[6]   Fine-needle aspiration in. PreservCyt®:: a novel and reproducible method for possible ancillary proteomic pattern expression of breast neoplasms by SELDI-TOF [J].
Fowler, LJ ;
Lovell, MO ;
Izbicka, E .
MODERN PATHOLOGY, 2004, 17 (08) :1012-1020
[7]   Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population [J].
Kim, JE ;
Lee, KT ;
Lee, JK ;
Paik, SW ;
Rhee, JC ;
Choi, KW .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (02) :182-186
[8]   Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry [J].
Koopmann, J ;
Zhang, Z ;
White, N ;
Rosenzweig, J ;
Fedarko, N ;
Jagannath, S ;
Canto, MI ;
Yeo, CJ ;
Chan, DW ;
Goggins, M .
CLINICAL CANCER RESEARCH, 2004, 10 (03) :860-868
[9]   Pancreatic cancer [J].
Li, DH ;
Xie, KP ;
Wolff, R ;
Abbruzzese, JL .
LANCET, 2004, 363 (9414) :1049-1057
[10]   Plasma proteomic pattern as biomarkers for ovarian cancer [J].
Lin, YW ;
Lin, CY ;
Lai, HC ;
Chiou, JY ;
Chang, CC ;
Yu, MH ;
Chu, TY .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 :139-146